

Please cancel Claims 1-5, 14, and 29, without prejudice.

Please amend Claims 15-19 as follows:

15. (Amended) A monoclonal antibody to human IL-12 which consists of a p35 subunit and a p40 subunit forming a p75 heterodimer, wherein said monoclonal antibody

(a) immunologically reacts with an epitope presented by the p75 heterodimer of

human IL-12, but is not immunologically reactive with any epitope presented by said p40 subunit; and

(b) neutralizes at least about 90% of the bioactivity of human IL-12, wherein the antibody neutralizes at least about 90% bioactivity of human IL-12 by inhibiting IL-12 stimulated PHA-activated human lymphoblast proliferation wherein the concentration of said antibody is 0.5 μ g/ml and the concentration of said human IL-12 is 0.25 ng/ml.

D1
16. (Amended) A monoclonal antibody to human IL-12 which consists of a p35 subunit and a p40 subunit forming a p75 heterodimer, wherein said monoclonal antibody

(a) immunologically reacts with an epitope presented by the p75 heterodimer of human IL-12, but is not immunologically reactive with any epitope presented by said p40 subunit; and

(b) neutralizes at least about 90% of the bioactivity of human IL-12, wherein the antibody neutralizes at least about 90% bioactivity of human IL-12 by inhibiting IL-12 stimulated IFN- γ production wherein the concentration of the antibody is 0.5 μ g/ml and the concentration of said human IL-12 is 0.25 ng/ml.

17. (Amended) The antibody of claim 15, wherein the antibody cross reacts with rhesus monkey IL-12.

D1
18. (Amended) The antibody of claim 15, wherein the antibody is humanized.

19. (Amended) The antibody of claim 15, wherein the antibody is produced by a hybridoma.

Please add new Claims 37-40:

37. (New) The antibody of claim 16, wherein the antibody cross reacts with rhesus monkey IL-12.

D2
38. (New) The antibody of claim 16, wherein the antibody is humanized.

39. (New) The antibody of claim 16, wherein the antibody is produced by a hybridoma.

40. (New) The antibody of claim 39, wherein the antibody has been humanized.

REMARKS

Claims 1-5, 14-20, and 29 are pending in this application. With this Amendment, Claims 1-5, 14, and 29 are canceled without prejudice to Applicants' right to pursue the subject matter of the canceled claims in one or more subsequent applications. Applicants do not acquiesce to the propriety of the outstanding rejection of Claims 1-5, 14, and, 29, and elect to cancel these claims solely to expedite passage of the non-canceled claims to issuance. In addition, Claims 15 and 16 are amended into independent form, and Claims 17-19 are amended to depend from Claim 15. Further, new Claims 37-40, which correspond to amended Claims 17-19 and Claim 20, but depend from amended Claim 16 rather than Claim